 Enanta Pharmaceuticals Inc NASDAQ: ENTA has announced data from the first two dose cohorts of Part 2 of its Phase 1b study evaluating EDP-514 in chronic hepatitis B virus HBV patients already being treated with a nucleoside reverse transcriptase inhibitor NUC. The data demonstrated that EDP-514, the Companys novel class II oral HBV core inhibitor, was safe and well-tolerated, displayed pharmacokinetics PK supportive of once-daily dosing, and resulted in a mean reduction in HBV RNA of 1 log. 